Non-invasive diagnostics Breathomix offers a non-invasive breath analysis platform (BreathBase) combining eNose, SpiroNose and an AI-driven database, presenting a compelling case for clinical adoption and expanding beyond niche markets into routine diagnostic workflows.

Clinical study momentum Proactive engagement in multi-centre prospective clinical studies and past collaboration with Evalan indicate a readiness to generate evidence and accelerate adoption, presenting opportunities for system integration with clinical trial networks and hospital research programs.

AI powered platform An AI-driven analysis of exhaled biomarkers with real-time, on-site capabilities aligns Breathomix with precision medicine trends and offers potential for partnerships with health IT vendors, diagnostic labs, and payer-backed pilots.

Early stage traction Current revenue range and small team size suggest a nimble, high-growth fintech-like medical startup dynamic; ideal entry points include pilot deployments, co-development contracts, and channel partnerships with larger medical device distributors.

Expand disease scope The stated focus on chronic respiratory diseases, cancer and infectious diseases creates multiple verticals for expansion; sales opportunities exist in hospitals, clinics, and specialty centers seeking non-invasive screening and early detection capabilities.